Amarin CEO willing to wait for the best AMR101 deal; Actelion ponders consequences of macitentan failure;

@FierceBiotech: Obesity field gets boost with $6.2M round for Gelesis. Story | Follow @FierceBiotech

@JohnCFierce: So, let's see. Forest's big product is losing protection next year. Its CEO is fighting the feds and here comes Icahn. | Follow @JohnCFierce

> With a regulatory filing for the cholesterol drug AMR101 now in the works, Amarin CEO Joe Zakrzewski tells Bloomberg that the company could do a deal sometime soon or wait until next year as the value of the product becomes better known. Story

> An Actelion executive told Der Sonntag that that if its closely watched macitentan program--its successor to Tracleer--turns out to be a failure, then "all strategic options are possible, up to and including a sale." Report

> Quintiles has struck a deal to invest in Kareus Therapeutics as they partner on pushing preclinical drugs for Alzheimer's and type 2 diabetes into clinical trials. Story

> Tetragenetics announced today that Dr. Marco Cacciuttolo has been appointed president and CEO. Release

> Thoratec CFO David Smith has resigned and been replaced by Roxanne Oulman on an interim basis. Story

Pharma News

@FiercePharma: UCB to pay $34M for off-label marketing. Article | Follow @FiercePharma

> Judge won't dismiss antitrust suits over GSK's Flonase. Report

> European patent office yanks Nexium protection. Item

> FDA tags new GSK-Valeant med as controlled substance. News

> Justice Dep't subpoenas Gilead on manufacturing. Report

> Pfizer just might postpone Viagra's patent cliff. Story

Biotech IT News

> PacBio fosters software community with 3rd-gen sequencer release. Article

> GenomeQuest taps former Roche exec to key post. Story

> Accelrys faces PerkinElmer in race to move labs from paper to pixel notebooks. Report

> PatientsLikeMe enhances recruitment for clinical trials via social network. Item

> Assay Depot lands $1.7M to take pharma research buying to the cloud. Report

Medical Device News

> GE to open new Israeli R&D center. Article

> MIT, UMass look to protect implantable devices from attack. Article

> Meridian tests detect toxins produced by E. coli strain plaguing Europe. Report

> ACT gets CE Mark for TEMPASURE system. Story

> Senators ask for IG investigation into PODs. Item

And Finally... Investigators say that women afflicted by heart disease can drink a few cups of coffee every day and still expect to live just as long as non-coffee drinkers. Report

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.